Transcatheter aortic valve implantation with a mechanical-expandable device: when perfection is hung on a ‘wire’

@article{Tamburino2017TranscatheterAV,
  title={Transcatheter aortic valve implantation with a mechanical-expandable device: when perfection is hung on a ‘wire’},
  author={Corrado Tamburino and Marco Barbanti},
  journal={European Heart Journal},
  year={2017},
  volume={38},
  pages={3367–3369}
}
Since the first-in-human transcatheter aortic valve implantation (TAVI) performed by Alain Cribier in 2002, this innovative procedure has had widespread recognition as the treatment of choice for severe aortic stenosis in inoperable patients and as a reasonable alternative to conventional surgical aortic valve replacement in patients with intermediate and high surgical risk. In the last 15 years, TAVI technology has gone from strength to strength, transforming a challenging intervention into a… 

Figures from this paper

Managing aortic stenosis with TAVI or surgery: risk assessement and long-term outcome.

The rapid technological evolution from early to current-generation transcatheter aortic valve implantation or TAVI systems with low-profile delivery catheters, bioprosthetic valves with proven midterm durability, and improved positioning and retrieval features have facilitated their use and improved outcomes, and further improvements are under way.

References

SHOWING 1-10 OF 17 REFERENCES

Percutaneous implantation of the first repositionable aortic valve prosthesis in a patient with severe aortic stenosis

  • L. BuellesfeldU. GerckensE. Grube
  • Medicine, Engineering
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
  • 2008
The first‐in‐man experience with the new self‐expanding Lotus™ Valve prosthesis composed of a nitinol frame with implemented bovine pericardial leaflets which is designed to address technical shortcomings, being repositionable and covered by a flexible membrane to seal paravalvular gaps.

Transfemoral aortic valve replacement with the repositionable Lotus Valve System in high surgical risk patients: the REPRISE I study.

  • I. MeredithS. Worthley K. Dawkins
  • Medicine, Biology
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
  • 2014
Initial results support proof-of-concept with the Lotus Valve for TAVR, and partial resheathing to facilitate accurate placement was attempted and successfully performed in four patients; none required full retrieval.

Insights into the need for permanent pacemaker following implantation of the repositionable LOTUS valve for transcatheter aortic valve replacement in 250 patients: results from the REPRISE II trial with extended cohort.

  • N. DumonteilI. Meredith K. Dawkins
  • Medicine
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
  • 2017
Careful attention to valve sizing and implant depth may help to reduce the rate of PPM with the LOTUS valve.

TAVI with current CE-marked devices: strategies for optimal sizing and valve delivery.

  • L. van GilsD. Tchétché N. Van Mieghem
  • Medicine
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
  • 2016
A practical overview of current CE-marked transcatheter aortic valve designs with a focus on respective sizing algorithms and delivery strategies is provided.

Transcatheter aortic valve replacement with new-generation devices: A systematic review and meta-analysis.

Safety and efficacy of a repositionable and fully retrievable aortic valve used in routine clinical practice: the RESPOND Study

The results of RESPOND confirm the safety and efficacy of TAVI with the Lotus Valve in routine clinical practice.